Get the Stockscreener App
1.66
2.35%
-0.04
Pre-market:
1.76
0.10
+6.02%
NanoViricides Inc stock is traded at $1.66, with a volume of 180.05K.
It is down -2.35% in the last 24 hours and up +16.08% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.70
Open:
$1.72
24h Volume:
180.05K
Relative Volume:
1.02
Market Cap:
$26.68M
Revenue:
-
Net Income/Loss:
$-8.29M
P/E Ratio:
-2.3714
EPS:
-0.7
Net Cash Flow:
$-6.47M
1W Performance:
+8.50%
1M Performance:
+16.08%
6M Performance:
+21.17%
1Y Performance:
+16.08%
1-Day Range:
$1.65
$1.7499
1-Week Range:
$1.51
$1.8678
52-Week Range:
$0.94
$1.9195
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.66 | 29.63M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
How to use Fibonacci retracement on NanoViricides Inc.Market Risk Analysis & Growth Focused Entry Reports - newser.com
How NanoViricides Inc. stock trades after earnings2025 Institutional Moves & Fast Momentum Stock Entry Tips - newser.com
Why NanoViricides Inc. stock appeals to dividend seekersEarnings Summary Report & Community Supported Trade Ideas - newser.com
Combining machine learning predictions for NanoViricides Inc.Trade Volume Summary & AI Powered Buy and Sell Recommendations - newser.com
Will NanoViricides Inc. stock split attract more investorsQuarterly Profit Report & Fast Gain Swing Trade Alerts - newser.com
Has NanoViricides Inc. found a price floorTrade Performance Summary & Detailed Earnings Play Alerts - newser.com
Using portfolio simulators with NanoViricides Inc. includedInflation Watch & Technical Pattern Alert System - newser.com
NanoViricides Dual Track Clinical Strategy Explained by a Research ReportBroad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses - The Holland Sentinel
Can NanoViricides Inc. stock hit consensus price targetsStop Loss & Capital Efficient Trade Techniques - newser.com
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive - Ashland Times-Gazette
Why NanoViricides Inc. stock is upgraded to buyWeekly Market Outlook & Low Volatility Stock Recommendations - newser.com
How NanoViricides Inc. (NV3P) stock trades after rate cutsForecast Cut & Expert Curated Trade Ideas - newser.com
NanoViricides targets broad-spectrum virus threats – ICYMI - Proactive financial news
Identifying reversal signals in NanoViricides Inc.2025 Volume Leaders & Long-Term Growth Stock Strategies - newser.com
Detecting support and resistance levels for NanoViricides Inc.Weekly Trade Report & Community Verified Trade Alerts - newser.com
What MACD trends signal for NanoViricides Inc. stockQuarterly Trade Summary & Precise Swing Trade Alerts - newser.com
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 - The Sheboygan Press
NanoViricides Reports Promising Anti-Measles Results for Broad-Spectrum Antiviral Candidate NV-387 - citybuzz -
NanoViricides (NYSE American: NNVC): NV-387 increases survival 130% in measles model - Stock Titan
How to build a dashboard for NanoViricides Inc. stockGap Up & Safe Capital Allocation Plans - newser.com
Why NanoViricides Inc. stock is a must watch in 2025July 2025 Volume & Daily Growth Stock Investment Tips - fcp.pa.gov.br
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):